SEARCH

SEARCH BY CITATION

References

  • 1
    Cantley LC (2002) The phosphoinositide 3-kinase pathway. Science 296, 16551657.
  • 2
    Yuan TL & Cantley LC (2008) PI3K pathway alterations in cancer: variations on a theme. Oncogene 27, 54975510.
  • 3
    Zhao L & Vogt PK (2008) Class I PI3K in oncogenic cellular transformation. Oncogene 27, 54865496.
  • 4
    Miller TW, Rexer BN, Garrett JT & Arteaga CL (2011) Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer. Breast Cancer Res 13, 224. doi: 10.1186/bcr3039.
  • 5
    Bachman KE, Argani P, Samuels Y, Silliman N, Ptak J, Szabo S, Konishi H, Karakas B, Blair BG, Lin C et al. (2004) The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther 3, 772775.
  • 6
    Kadota M, Sato M, Duncan B, Ooshima A, Yang HH, Diaz-Meyer N, Gere S, Kageyama S, Fukuoka J, Nagata T et al. (2009) Identification of novel gene amplifications in breast cancer and coexistence of gene amplification with an activating mutation of PIK3CA. Cancer Res 69, 73577365.
  • 7
    Levine DA, Bogomolniy F, Yee CJ, Lash A, Barakat RR, Borgen PI & Boyd J (2005) Frequent mutation of the PIK3CA gene in ovarian and breast cancers. Clin Cancer Res 11, 28752878.
  • 8
    Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ et al. (2004) High frequency of mutations of the PIK3CA gene in human cancers. Science 304, 554. doi: 10.1126/science.1096502.
  • 9
    Wu G, Xing M, Mambo E, Huang X, Liu J, Guo Z, Chatterjee A, Goldenberg D, Gollin SM, Sukumar S et al. (2005) Somatic mutation and gain of copy number of PIK3CA in human breast cancer. Breast Cancer Res 7, R609R616.
  • 10
    Barbareschi M, Buttitta F, Felicioni L, Cotrupi S, Barassi F, Del Grammastro M, Ferro A, Dalla Palma P, Galligioni E & Marchetti A (2007) Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas. Clin Cancer Res 13, 60646069.
  • 11
    Miller TW (2012) Initiating breast cancer by PIK3CA mutation. Breast Cancer Res 14, 301. doi:10.1186/bcr3103.
  • 12
    Saal LH, Holm K, Maurer M, Memeo L, Su T, Wang X, Yu JS, Malmstrom PO, Mansukhani M, Enoksson J et al. (2005) PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 65, 25542559.
  • 13
    Bader AG, Kang S, Zhao L & Vogt PK (2005) Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer 5, 921929.
  • 14
    Bader AG, Kang S & Vogt PK (2006) Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proc Natl Acad Sci USA 103, 14751479.
  • 15
    Isakoff SJ, Engelman JA, Irie HY, Luo J, Brachmann SM, Pearline RV, Cantley LC & Brugge JS (2005) Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res 65, 1099211000.
  • 16
    Zhao JJ, Liu Z, Wang L, Shin E, Loda MF & Roberts TM (2005) The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells. Proc Natl Acad Sci USA 102, 1844318448.
  • 17
    Miron A, Varadi M, Carrasco D, Li H, Luongo L, Kim HJ, Park SY, Cho EY, Lewis G, Kehoe S et al. (2010) PIK3CA mutations in in situ and invasive breast carcinomas. Cancer Res 70, 56745678.
  • 18
    Boyault S, Drouet Y, Navarro C, Bachelot T, Lasset C, Treilleux I, Tabone E, Puisieux A & Wang Q (2012) Mutational characterization of individual breast tumors: TP53 and PI3K pathway genes are frequently and distinctively mutated in different subtypes. Breast Cancer Res Treat 132, 2939.
  • 19
    Campbell IG, Russell SE, Choong DY, Montgomery KG, Ciavarella ML, Hooi CS, Cristiano BE, Pearson RB & Phillips WA (2004) Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 64, 76787681.
  • 20
    Dunlap J, Le C, Shukla A, Patterson J, Presnell A, Heinrich MC, Corless CL & Troxell ML (2010) Phosphatidylinositol-3-kinase and AKT1 mutations occur early in breast carcinoma. Breast Cancer Res Treat 120, 409418.
  • 21
    Dupont Jensen J, Laenkholm AV, Knoop A, Ewertz M, Bandaru R, Liu W, Hackl W, Barrett JC & Gardner H (2011) PIK3CA mutations may be discordant between primary and corresponding metastatic disease in breast cancer. Clin Cancer Res 17, 667677.
  • 22
    Kalinsky K, Jacks LM, Heguy A, Patil S, Drobnjak M, Bhanot UK, Hedvat CV, Traina TA, Solit D, Gerald W et al. (2009) PIK3CA mutation associates with improved outcome in breast cancer. Clin Cancer Res 15, 50495059.
  • 23
    Li H, Zhu R, Wang L, Zhu T, Li Q, Chen Q, Wang H & Zhu H (2010) PIK3CA mutations mostly begin to develop in ductal carcinoma of the breast. Exp Mol Pathol 88, 150155.
  • 24
    Li SY, Rong M, Grieu F & Iacopetta B (2006) PIK3CA mutations in breast cancer are associated with poor outcome. Breast Cancer Res Treat 96, 9195.
  • 25
    Perez-Tenorio G, Alkhori L, Olsson B, Waltersson MA, Nordenskjold B, Rutqvist LE, Skoog L & Stal O (2007) PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer. Clin Cancer Res 13, 35773584.
  • 26
    Lai YL, Mau BL, Cheng WH, Chen HM, Chiu HH & Tzen CY (2008) PIK3CA exon 20 mutation is independently associated with a poor prognosis in breast cancer patients. Ann Surg Oncol 15, 10641069.
  • 27
    Mangone FR, Bobrovnitchaia IG, Salaorni S, Manuli E & Nagai MA (2012) PIK3CA exon 20 mutations are associated with poor prognosis in breast cancer patients. Clinics 67, 12851290.
  • 28
    Eichhorn PJ, Gili M, Scaltriti M, Serra V, Guzman M, Nijkamp W, Beijersbergen RL, Valero V, Seoane J, Bernards R et al. (2008) Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res 68, 92219230.
  • 29
    Kataoka Y, Mukohara T, Shimada H, Saijo N, Hirai M & Minami H (2010) Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines. Ann Oncol 21, 255262.
  • 30
    Miller TW, Forbes JT, Shah C, Wyatt SK, Manning HC, Olivares MG, Sanchez V, Dugger TC, de Matos Granja N, Narasanna A et al. (2009) Inhibition of mammalian target of rapamycin is required for optimal antitumor effect of HER2 inhibitors against HER2-overexpressing cancer cells. Clin Cancer Res 15, 72667276.
  • 31
    Borowsky AD (2011) Choosing a mouse model: experimental biology in context – the utility and limitations of mouse models of breast cancer. Cold Spring Harbor Perspect Biol 3, a009670. doi: 10.1101/cshperspect.a009670.
  • 32
    Adams JR, Xu K, Liu JC, Agamez NM, Loch AJ, Wong RG, Wang W, Wright KL, Lane TF, Zacksenhaus E et al. (2011) Cooperation between Pik3ca and p53 mutations in mouse mammary tumor formation. Cancer Res 71, 27062717.
  • 33
    Liu P, Cheng H, Santiago S, Raeder M, Zhang F, Isabella A, Yang J, Semaan DJ, Chen C, Fox EA et al. (2011) Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms. Nat Med 17, 11161120.
  • 34
    Meyer DS, Brinkhaus H, Muller U, Muller M, Cardiff RD & Bentires-Alj M (2011) Luminal expression of PIK3CA mutant H1047R in the mammary gland induces heterogeneous tumors. Cancer Res 71, 43444351.
  • 35
    Tikoo A, Roh V, Montgomery KG, Ivetac I, Waring P, Pelzer R, Hare L, Shackleton M, Humbert P & Phillips WA (2012) Physiological levels of Pik3ca(H1047R) mutation in the mouse mammary gland results in ductal hyperplasia and formation of ERalpha-positive tumors. PLoS One 7, e36924.
  • 36
    Yuan W, Stawiski E, Janakiraman V, Chan E, Durinck S, Edgar KA, Kljavin NM, Rivers CS, Gnad F, Roose-Girma M et al. (2012) Conditional activation of Pik3ca(H1047R) in a knock-in mouse model promotes mammary tumorigenesis and emergence of mutations. Oncogene 32, 318326.
  • 37
    Soriano P (1999) Generalized lacZ expression with the ROSA26 Cre reporter strain. Nat Genet 21, 7071.
  • 38
    Srinivas S, Watanabe T, Lin CS, William CM, Tanabe Y, Jessell TM & Costantini F (2001) Cre reporter strains produced by targeted insertion of EYFP and ECFP into the ROSA26 locus. BMC Dev Biol 1, 4. doi: 10.1186/1471-213X-1-4.
  • 39
    Wagner KU, Wall RJ, St-Onge L, Gruss P, Wynshaw-Boris A, Garrett L, Li M, Furth PA & Hennighausen L (1997) Cre-mediated gene deletion in the mammary gland. Nucleic Acids Res 25, 43234330.
  • 40
    Andrechek ER, White D & Muller WJ (2005) Targeted disruption of ErbB2/Neu in the mammary epithelium results in impaired ductal outgrowth. Oncogene 24, 932937.
  • 41
    Wagner KU, McAllister K, Ward T, Davis B, Wiseman R & Hennighausen L (2001) Spatial and temporal expression of the Cre gene under the control of the MMTV-LTR in different lines of transgenic mice. Transgenic Res 10, 545553.
  • 42
    Wintermantel TM, Mayer AK, Schutz G & Greiner EF (2002) Targeting mammary epithelial cells using a bacterial artificial chromosome. Genesis 33, 125130.
  • 43
    Gunther EJ, Belka GK, Wertheim GB, Wang J, Hartman JL, Boxer RB & Chodosh LA (2002) A novel doxycycline-inducible system for the transgenic analysis of mammary gland biology. FASEB J 16, 283292.
  • 44
    Stambolic V, Tsao MS, Macpherson D, Suzuki A, Chapman WB & Mak TW (2000) High incidence of breast and endometrial neoplasia resembling human Cowden syndrome in pten+/– mice. Cancer Res 60, 36053611.
  • 45
    Li G, Robinson GW, Lesche R, Martinez-Diaz H, Jiang Z, Rozengurt N, Wagner KU, Wu DC, Lane TF, Liu X et al. (2002) Conditional loss of PTEN leads to precocious development and neoplasia in the mammary gland. Development 129, 41594170.
  • 46
    Dourdin N, Schade B, Lesurf R, Hallett M, Munn RJ, Cardiff RD & Muller WJ (2008) Phosphatase and tensin homologue deleted on chromosome 10 deficiency accelerates tumor induction in a mouse model of ErbB-2 mammary tumorigenesis. Cancer Res 68, 21222131.
  • 47
    Hollander MC, Blumenthal GM & Dennis PA (2011) PTEN loss in the continuum of common cancers, rare syndromes and mouse models. Nat Rev Cancer 11, 289301.
  • 48
    Renner O, Blanco-Aparicio C, Grassow M, Canamero M, Leal JF & Carnero A (2008) Activation of phosphatidylinositol 3-kinase by membrane localization of p110alpha predisposes mammary glands to neoplastic transformation. Cancer Res 68, 96439653.
  • 49
    Buttitta F, Felicioni L, Barassi F, Martella C, Paolizzi D, Fresu G, Salvatore S, Cuccurullo F, Mezzetti A, Campani D et al. (2006) PIK3CA mutation and histological type in breast carcinoma: high frequency of mutations in lobular carcinoma. J Pathol 208, 350355.
  • 50
    Maruyama N, Miyoshi Y, Taguchi T, Tamaki Y, Monden M & Noguchi S (2007) Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women. Clin Cancer Res 13, 408414.
  • 51
    Quereda V, Martinalbo J, Dubus P, Carnero A & Malumbres M (2007) Genetic cooperation between p21Cip1 and INK4 inhibitors in cellular senescence and tumor suppression. Oncogene 26, 76657674.
  • 52
    Sotillo R, Dubus P, Martin J, de la Cueva E, Ortega S, Malumbres M & Barbacid M (2001) Wide spectrum of tumors in knock-in mice carrying a Cdk4 protein insensitive to INK4 inhibitors. EMBO J 20, 66376647.
  • 53
    Meyer DS & Bentires-Alj M (2010) Can phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibition ERase them all? Breast Cancer Res 12, 315. doi: 10.1186/bcr2718.
  • 54
    Sheppard K, Kinross KM, Solomon B, Pearson RB & Phillips WA (2012) Targeting PI3 kinase/AKT/mTOR signaling in cancer. Crit Rev Oncog 17, 6995.
  • 55
    Courtney KD, Corcoran RB & Engelman JA (2010) The PI3K pathway as drug target in human cancer. J Clin Oncol 28, 10751083.
  • 56
    Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, Upadhyay R, Maira M, McNamara K, Perera SA, Song Y et al. (2008) Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 14, 13511356.